NEW YORK (GenomeWeb) – Using several large cohorts of rheumatoid arthritis patients, researchers have shown for the first time that variations in the HLA-DRB1 gene that are known to confer increased susceptibility to the disease are also associated with more severe symptoms, and potentially with overall outcome and better response to anti-TNF drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.